| 01.05.22 | Oral COVID vaccine developer snags supply deal; EyeD lands $51M to take glaucoma implant into clinic

Laden...

2 jaren geleden

Html
Tekst

This week's sponsor is Medical Affair's Strategic Summit.

Today's Rundown

Oravax inks oral COVID-19 vaccine supply deal amid talks about public listing EyeD lands $51M to take glaucoma implant into the clinic Arcutis reups ahead of critical year for topical drug delivery tech, securing $225M debt financing to fund product launch, pivotal readouts SanPlena sets out to show wearable patches are the key to faster weight loss 2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs

Featured Story

Oravax inks oral COVID-19 vaccine supply deal amid talks about public listing

By Nick Paul Taylor

Oravax Medical has taken an early step toward the commercialization of its oral COVID-19 vaccine by entering into a deal to ship 10 million doses of the clinical-phase candidate to Southeast Asia.

Webinar: How to choose the appropriate pre-filled syringe and enhanced delivery system for your product

Wednesday, January 19 | 11 am ET / 8am PT

In an environment that calls for more convenient delivery systems, we will guide you on how to make the right choice for your product. This webinar will cover selection criteria for pre-filled syringes and enhanced delivery systems. Register to learn more.

EyeD lands $51M to take glaucoma implant into the clinic

By Nick Paul Taylor

EyeD Pharma’s new spin on an old molecule has attracted investor support, giving it 45 million euros ($51 million) to advance an implant that could challenge AbbVie for the glaucoma market.

Arcutis reups ahead of critical year for topical drug delivery tech, securing $225M debt financing to fund product launch, pivotal readouts

By Nick Paul Taylor

Arcutis Biotherapeutics has topped up its bank balance ahead of a critical year. With 2022 bringing a trio of pivotal clinical trial readouts and potentially a FDA approval, the topical drug delivery specialist has turned to SLR Capital Partners for a $225 million loan facility.

SanPlena sets out to show wearable patches are the key to faster weight loss

By Nick Paul Taylor

Can wearable drug delivery patches enable obese patients to lose 15% of their body weight in as little as two months? That is the question EOFlow and Zihipp are aiming to answer by creating joint venture SanPlena

2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs

By Eric Sagonowsky

Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 batch of new drug approvals clearly demonstrates that the sector has learned how to operate in a pandemic.